Executive Summary
CGI Federal Inc., a Timken subsidiary, secured a $108M GSA delivery order for EPA IT enterprise development, with $523M potential value through options to 2030, signaling bullish momentum in federal IT contracting. No outlays yet but 47 subawards at $15M indicate early subcontracting activity. Investors gain exposure to long-duration gov IT spend via performance-driven upside.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior New Federal Contractors digest from March 27, 2026.
Investment Signals (1)
- CGI Federal Lands $108M EPA IT Award (HIGH)▲
$108M obligated under cost-plus contract (potential $523M with options) for EPA IT support via GSA FAS, extending to 2030.
Risk Flags (1)
- Execution [MEDIUM RISK]▼
Options may not exercise beyond 2026 end date; award fees tied to performance; $15M subawards across 47 recipients could erode margins.
Opportunities (1)
- ◆
Full $523M value unlock via option exercises by 2030; follow-on GSA task orders in EPA IT.
Sector Themes (1)
- ◆
GSA FAS vehicles funding large-scale IT enterprise support for environmental agencies.
Watch List (1)
- 👁
{"entity"=>"CGI Federal GSA Contract 47QFCA23F0030", "reason"=>"$108M obligated with $415M options at stake through 2030.", "trigger"=>"Option exercises or outlay increases >$10M"}
Get daily alerts with 1 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: New Federal Contractors
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals